CICC: First coverage of Contemporary Amperex Technology (03750) with a "outperform" rating and a target price of 580 Hong Kong dollars.
Contemporary Amperex Technology (CATL) has a solid competitive advantage, excellent profitability, and is leading the industry in technology. The company is a rare target with high dividends and high return on net assets. Its financial management is cautious, and its profit safety cushion is solid.
Zhongjin released a research report stating that Contemporary Amperex Technology (03750) was covered for the first time, with an "outperform" rating and a target price of 580 Hong Kong dollars, corresponding to a 26.5 times price-earnings ratio in 2026. The bank expects the company to achieve earnings per share of 15.27 yuan and 19.74 yuan in 2025 and 2026, respectively, with a compound annual growth rate of 31.6% from 2024 to 2026. Meanwhile, the rating for Contemporary Amperex Technology (300750.SZ) A shares in China remains as "outperform" with an unchanged target price of 445 yuan.
The report points out that Contemporary Amperex Technology is a leading global company in power and energy storage batteries, leading the way in exploring overseas market growth potential. Emerging applications continue to emerge, driving continuous growth in lithium battery demand. Contemporary Amperex Technology has a solid competitive advantage, excellent profitability, and industry-leading technology. The company is a rare target with high dividends and high return on net assets, prudent financial management, and a solid earnings safety cushion.
Related Articles

JD LOGISTICS (02618): Laura J. Peterson is appointed as an independent non-executive director.

ZYY(08223): Hu Tao appointed as an independent non-executive director

Fill the domestic gap! GRAND PHARMA (00512) The world's first approved adrenaline nasal spray brand OptiNose has been approved for domestic launch.
JD LOGISTICS (02618): Laura J. Peterson is appointed as an independent non-executive director.

ZYY(08223): Hu Tao appointed as an independent non-executive director

Fill the domestic gap! GRAND PHARMA (00512) The world's first approved adrenaline nasal spray brand OptiNose has been approved for domestic launch.

RECOMMEND

Not Just “Power Shortages,” Delays Will Become The Key Theme For U.S. Data Centers In 2026
26/12/2025

Hang Seng Index Rises 33% This Year, Best Five‑Year Performance; Multiple Institutions Forecast Breakthrough Above 30,000 Next Year
26/12/2025

Gold Rally Has Further To Run, JPMorgan Bullish: Prices Could Reach USD 5,055 By Year‑End 2026
26/12/2025


